Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company suffered a setback when the FDA issued a complete response letter to the supplemental new drug application for Nuplazid for treating dementia-related psychosis. Acadia resubmitted the supplemental new drug application to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis. Notably, several additional studies on Nuplazid n targeting different CNS indications, such as?dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and as an adjunctive treatment of major depressive disorder (MDD) are currently underway.
| Revenue (Most Recent Fiscal Year) | $957.80M |
| Net Income (Most Recent Fiscal Year) | $226.45M |
| PE Ratio (Current Year Earnings Estimate) | 43.58 |
| PE Ratio (Trailing 12 Months) | 31.93 |
| PEG Ratio (Long Term Growth Estimate) | 4.64 |
| Price to Sales Ratio (Trailing 12 Months) | 3.65 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.75 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 30.80 |
| Pre-Tax Margin (Trailing 12 Months) | 26.58% |
| Net Margin (Trailing 12 Months) | 22.97% |
| Return on Equity (Trailing 12 Months) | 17.46% |
| Return on Assets (Trailing 12 Months) | 10.75% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.88 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.80 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.79 |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.40 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.11 |
| Earnings per Share (Most Recent Fiscal Year) | $0.67 |
| Diluted Earnings per Share (Trailing 12 Months) | $1.37 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 167.36M |
| Free Float | 123.01M |
| Market Capitalization | $3.63B |
| Average Volume (Last 20 Days) | 2.57M |
| Beta (Past 60 Months) | 0.65 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 26.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 96.71% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |